Metabolic testing for GLP-1 treatment
Metabolic blood work — including HbA1c, fasting glucose, lipid panel, thyroid function, and sometimes additional markers — helps personalize GLP-1 treatment, flag contraindications, and establish a baseline to track cardiometabolic improvement over time. The FirstCall platform connects you with an independent, board-certified physician who can order labs at a partner laboratory and review results before starting or adjusting GLP-1 therapy.
HbA1c, fasting glucose, lipids, TSH, basic metabolic panel
personalizes dosing, flags contraindications, baseline tracking
at a partner laboratory near you
Educational content. Last clinically reviewed by the FirstCall Clinical Editorial Board, June 2026. The FirstCall platform provides access to independent, licensed physicians; final clinical decisions rest with the prescribing physician.
Personalized treatment starts with your metabolic baseline
Not everyone with the same BMI has the same metabolic profile. Baseline labs help match you to the right medication.
The FDA approval for GLP-1 weight loss medications is not one-size-fits-all. A patient with a high A1C and borderline kidney function needs a different approach than one with normal glucose. Your metabolic baseline drives medication selection, dosing, and safety screening.
Beyond selecting the right medication, baseline labs document your starting point. GLP-1 medications produce significant cardiometabolic benefits beyond weight loss — A1C reduction, blood pressure improvement, lipid improvement. Follow-up labs at 3 and 6 months make these improvements visible and clinically meaningful.
Recommended baseline lab panel
Screens for type 2 diabetes and prediabetes. GLP-1s normalize blood glucose in over 70% of prediabetic patients. Critical for medication selection.
Establishes blood sugar baseline and identifies insulin resistance patterns alongside A1C.
Cholesterol, LDL, HDL, and triglycerides. GLP-1s improve lipid profiles — baseline establishes the magnitude of improvement.
GLP-1s carry a boxed warning for thyroid C-cell tumor risk. TSH baseline and personal/family history review are important safety steps.
Kidney function (creatinine, eGFR) screens for GLP-1 contraindications. Electrolytes and liver enzymes establish baseline.
Identifies anemia or other conditions affecting energy and treatment response.
What your labs change about your treatment
A high A1C points toward Ozempic® (approved for type 2 diabetes). Normal glucose with obesity favors Wegovy® or Zepbound®. Labs drive this decision, not just BMI.
Kidney impairment, thyroid cancer history, or pancreatitis risk prevents starting a medication that could cause harm. Labs catch what questionnaires miss.
GLP-1s normalize blood glucose in over 70% of prediabetic patients. An A1C of 5.8% you did not know about could become 5.3% at six months — a clinically meaningful reversal.
Follow-up labs at 3 and 6 months document cardiometabolic improvements: A1C reduction, blood pressure normalization, lipid improvement — outcomes beyond the scale.
Frequently asked questions
Clear answers about your GLP-1 program.
Related programs
All options available through Physicians on the FirstCall platform.
